CN104622893A - Suspension containing calcium carbonate and preparation method as well as usage thereof - Google Patents
Suspension containing calcium carbonate and preparation method as well as usage thereof Download PDFInfo
- Publication number
- CN104622893A CN104622893A CN201310573059.5A CN201310573059A CN104622893A CN 104622893 A CN104622893 A CN 104622893A CN 201310573059 A CN201310573059 A CN 201310573059A CN 104622893 A CN104622893 A CN 104622893A
- Authority
- CN
- China
- Prior art keywords
- suspension
- calcium carbonate
- preparation
- calcium
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 106
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims abstract description 50
- 239000000725 suspension Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000375 suspending agent Substances 0.000 claims abstract description 13
- 206010006956 Calcium deficiency Diseases 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 13
- 229940013618 stevioside Drugs 0.000 claims description 13
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 13
- 235000019202 steviosides Nutrition 0.000 claims description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 12
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000000811 xylitol Substances 0.000 claims description 12
- 235000010447 xylitol Nutrition 0.000 claims description 12
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 12
- 229960002675 xylitol Drugs 0.000 claims description 12
- 241000416162 Astragalus gummifer Species 0.000 claims description 10
- 229920001615 Tragacanth Polymers 0.000 claims description 10
- 235000010489 acacia gum Nutrition 0.000 claims description 10
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 10
- 235000010487 tragacanth Nutrition 0.000 claims description 10
- 229940116362 tragacanth Drugs 0.000 claims description 10
- 230000002421 anti-septic effect Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
- 239000000196 tragacanth Substances 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000001727 glucose Nutrition 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HZVFRKSYUGFFEJ-YVECIDJPSA-N (2r,3r,4s,5r)-7-phenylhept-6-ene-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=CC1=CC=CC=C1 HZVFRKSYUGFFEJ-YVECIDJPSA-N 0.000 claims description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 229960003885 sodium benzoate Drugs 0.000 claims description 4
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960002737 fructose Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 20
- 239000011575 calcium Substances 0.000 description 19
- 229910052791 calcium Inorganic materials 0.000 description 19
- 238000004062 sedimentation Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a suspension containing calcium carbonate and preparation method as well as usage thereof. Weight ratio of calcium carbonate to a suspending agent in the suspension is 0.2-3.0:1(w/w). The suspension can be used as a preparation for treating or preventing calcium deficiency.
Description
Technical field
The present invention relates to medical art, particularly relate to a kind of new calcium supplementing preparation and preparation method thereof.
Background technology
Calcium forms the most important material of skeleton, and the calcium that human body absorbs from meals and nutriment, through osteoblastic effect, is deposited on skeleton, to ensure that skeleton is effectively strong.But skeleton not once be formed, just changes never again.Along with the increase at age, the level of digesting and assimilating of human body declines, there is change in hormonal readiness, calcium in skeleton can run off at leisure, and cause skeleton to become soft, fragile, osteoporosis also comes one after another, body reduces the absorption of calcium, utilization rate, in order to reduce bone-loss, reducing the danger of fracture, rationally replenish the calcium.
According to " Chinese residents nutrition and Health Situation " investigation report in 2004, the degree of Chinese's calcium deficiency was very serious, and resident's calcium intake is only 391 milligrams, is equivalent to 41% of recommended intake.
The calcium balance test display of presenium and old people, after 40 years old, intestinal calcium absorption declines, and declines 0.2% every year.Women is because of the reason of menopause, and calcium absorptivity declines 2.2% every year.The synergy increasing age and menopause cause women from 40 years old to 60 years old calcium absorptivity decline 20%-25%.So old people needs the intake of corresponding increase calcium.
At present, on market, most calcium preparation is all solid preparation, liquid preparation compares less, solid preparation takes inconvenience for old people, so develop a kind of loss that can either delay and resist sclerotin, it is calcareous that good supplementary needed by human body is wanted, gerontal patient and dysphagia patients can be made again to take medicine convenient product, there is positive social meaning.
Summary of the invention
The present invention aims to provide a kind of new calcium supplementing preparation.
In a first aspect of the present invention, provide a kind of suspension containing calcium carbonate, in described suspension, the weight ratio of calcium carbonate and suspending agent is 0.2-3.0:1; Preferred 0.3-2.0:1; More preferably 0.5-1.5:1.
In another preference, correctives, the antiseptic of 0.05-0.21w/v% and the essence of 0.1-5.0w/v% also containing 4-35w/v% in described suspension.
In another preference, described suspending agent be selected from ethyl cellulose, chitin, tragacanth, arabic gum, hydroxypropyl methylcellulose, polyvinylpyrrolidone, glucose, dextrin and pectin one or more; One or more preferably in tragacanth, arabic gum, polyvinylpyrrolidone and pectin; More preferably from tragacanth and/or arabic gum.
In another preference, described correctives be selected from stevioside, aspartame, fructose, xylitol and sucrose one or more; One or more preferably in xylitol, Aspartane and stevioside; More preferably from xylitol and/or stevioside.
In another preference, described antiseptic be selected from potassium sorbate, benzylidene sorbitol, sodium benzoate, methyl parahydroxybenzoate and ethylparaben one or more; One or more preferably in benzylidene sorbitol, sodium benzoate, methyl parahydroxybenzoate and ethylparaben; Be more preferably methyl parahydroxybenzoate.
In another preference, described calcium carbonate is precipitated calcium carbonate, and particle diameter is 10-30 μm.
In a second aspect of the present invention, provide a kind of preparation method of suspension provided by the invention as above, described method comprises step:
(1) suspending agent infiltrated by ethanol and water mixing, obtain solution 1;
(2) calcium carbonate and solution 1 are mixed, obtain solution 2;
(3) aqueous solution containing correctives, antiseptic and essence and solution 2 are mixed, obtain suspension provided by the invention as above.
In a third aspect of the present invention, provide a kind of purposes of suspension provided by the invention as above, the preparation being used as treatment or prevention calcium deficiency or the medicine of disease caused for the preparation for the treatment of or prevention calcium deficiency and/or calcium deficiency.
Accordingly, the invention provides a kind of loss that can either delay and resist sclerotin, it is calcareous that good supplementary needed by human body is wanted, and gerontal patient and dysphagia patients can be made again to take medicine convenient product, have positive social meaning.
Detailed description of the invention
Inventor, through extensive and deep research, finds calcium carbonate and suitable suspending agent to share can form a kind of suspension.On this basis, the present invention is completed.
Particularly, the invention provides a kind of suspension containing calcium carbonate, wherein the weight ratio of calcium carbonate and suspending agent is 0.2-3.0:1; Preferred 0.3-2.0:1; More preferably 0.5-1.5:1.Correctives, the antiseptic of 0.05-0.21w/v% and the essence of 0.1-5.0w/v% also containing 4-35w/v% in described suspension.
In one embodiment of the invention, described correctives is selected from xylitol and/or stevioside, in order to the use of diabetes, obesity, arteriosclerotic.
The present invention can use antiseptic and the essence of this area routine, only otherwise affecting suspension calcium supplementing effect provided by the invention plays.
There is no particular limitation for the calcium carbonate that the present invention uses, and can be the calcium carbonate meeting food sanitation standard of this area routine, be more preferably the calcium carbonate meeting medicinal standard.In one embodiment of the invention, the calcium carbonate of the use calcium carbonate that is high purity medical calcium carbonate disclosed in Chinese patent application CN200410052673.8 or screened by this kind of calcium carbonate and obtain.So-called screening refers to the particular requirement according to the distribution of particle sizes situation (as bulk density, compactness) of particle size distribution situation (as Malvern method particle size distribution volume mean diameter), granule etc., uses the method for this area routine to choose and obtains calcium carbonate.
The preparation method of the suspension containing calcium carbonate provided by the invention comprises step:
The first step, the suspending agent infiltrate ethanol and water mixing, obtain solution 1;
Second step, mixes calcium carbonate and solution 1, obtains solution 2;
3rd step, mixes the aqueous solution containing correctives, antiseptic and essence and solution 2, obtains the suspension containing calcium carbonate provided by the invention.
In one embodiment of the invention:
The first step is that after suspending agent arabic gum, tragacanth ethanol being infiltrated, the stirring and dissolving that adds water is solution 1;
Second step to join in solution 1 as solution 2 after calcium carbonate is made suspension, stirs; Described calcium carbonate crosses 600 mesh sieves;
3rd step is by after xylitol, stevioside, essence, methyl parahydroxybenzoate water dissolution, adds while stirring in solution 2, stirs, subpackage after high pressure steam sterilization, obtains the suspension containing calcium carbonate provided by the invention.
Suspension containing calcium carbonate provided by the invention can be used for preventing calcium loss, also can be used for the disease for the treatment of because calcium loss or calcium deficiency cause.The object that suspension provided by the invention can be used can be diabetics.
As used herein, " precipitated calcium carbonate " refers to the calcium carbonate obtained by inorganic chemical precipitation, because bulk density is less than natural heavy calcium carbonate, traditionally the calcium carbonate having the sedimentation method to produce is called precipitated calcium carbonate in China.
In this article, " treatment " one word comprise can cause the preventive of the pharmacy for asking and/or physiologic effect (that is, preventative), cure property or retentivity dispose.This effect is preferably finger and medically can partially or completely cures or prevent calcium loss.If reducing one or more symptom or clinical indices, namely to represent this treatment be " effectively ".
" prevention " refers to the means anti-processed to a kind of future event at this.Based on the Wen Yi preventing calcium loss herein, therefore, preventive disposal means as herein described can at any time be implemented.
" use " word to refer at this and directly use described suspension, and can using in individual body the suitable consumption person forming calcium carbonate.
Be used alternatingly the words such as " individual (subject) " or " patient (patient) " herein, it refers to the animal (comprising the mankind) that can accept the treatment of described suspension or prevention." individuality " or " patient " covers male and female two kinds of sexes at this, unless otherwise expressly specified.Therefore " individuality " or " patient " comprises any mammal, and include, but not limited to the mankind, inhuman primates, as mammal, Canis familiaris L., cat, horse, sheep, pig, cattle etc., it can carry out treating or preventing and benefit because utilizing described suspension.The animal being applicable to accepting the compounds of this invention and/or method treatment is preferably the mankind.In general, " patient " one word and " individuality " one word can alternating with each otherly use in this article.
When getting along well context conflict, this description singular noun used contains the complex number type of this noun; And during plural noun used, also contain the odd number type of this noun.
The above-mentioned feature that the present invention mentions, or the feature that embodiment is mentioned can combination in any.All features that this case description discloses can with any composition forms and use, each feature disclosed in description, anyly can provide identical, alternative characteristics that is impartial or similar object replaces.Therefore apart from special instruction, the feature disclosed is only general example that is impartial or similar features.
Major advantage of the present invention is:
1, in the suspension containing calcium carbonate provided by the invention, contained material is that metabolism does not need insulin to adopt material, expands use crowd, is applicable to diabetes simultaneously, obesity, arteriosclerotic take.
2, the suspension containing calcium carbonate provided by the invention can directly be taken, and has easy to use, the feature that bioavailability is high, especially makes gerontal patient and dysphagia patients take medicine convenient.
3, the preparation method of the suspension containing calcium carbonate provided by the invention, working condition and production technology are simple.
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, the usually conveniently conditioned disjunction condition of advising according to manufacturer.Unless otherwise indicated, otherwise all percent, ratio, ratio or number by weight.
Unit in percent weight in volume in the present invention is well-known to those skilled in the art, such as, refer to the weight of solute in the solution of 100 milliliters.
Unless otherwise defined, all specialties used in literary composition and scientific words and one skilled in the art the same meaning be familiar with.In addition, any method similar or impartial to described content and material all can be applicable in the inventive method.The use that better implementation method described in literary composition and material only present a demonstration.
Embodiment 1-3
The preparation (1000ml) of calcium carbonate suspension
| Embodiment 1 | Embodiment 2 | Embodiment 3 | |
| Calcium carbonate | 50g | 50g | 50g |
| Arabic gum | 90g | 60g | 30g |
| Tragacanth | 10g | 3g | 5g |
| Xylitol | 60 | 60 | 60 |
| Stevioside | 1g | 1g | 1g |
| Methyl parahydroxybenzoate | 1.2g | 1.2g | 1.2g |
| Essence | 1.0ml | 1.0ml | 1.0ml |
Test example 1-3
Calcium carbonate suspension stability checks
Sedimentation volume ratio inspection method: check sedimentation volume ratio according to " Chinese Pharmacopoeia " (2010 editions) two annex IO inspection methods, sedimentation volume ratio is not less than 0.90.
Inspection technique: unless otherwise specified, apparatus plug graduated cylinder measures test sample 50ml, close plug, and firmly jolting 1min, writes down the beginning height H o of suspended matter, leaves standstill 3 hours, writes down the final height H of suspended matter, be calculated as follows:
Sedimentation volume ratio=H/Ho
Table 1 calcium carbonate suspension stability checks
| Embodiment 1 | Embodiment 2 | Embodiment 3 | |
| Sedimentation volume ratio | 1 | 1 | 1 |
| Solution state | Glue-like, not easily flows | Thick, easily flow | Easy flowing |
| Suspension stability in March | Stable | Stable | Stable |
| Suspension stability in June | Stable | Stable | Stable |
| Suspension December stability | Stable | Stable | Instability, sedimentation |
Result shows, preparation stabilization in embodiment 1, but compares thickness, is not easy to take; In embodiment 2, relatively stable and be easy to take in preparation 12 months; In embodiment 3, preparation is easy to take, but the storage time is short, so the consumption of suspensoid in embodiment 2 is more rational.
Embodiment 4
The preparation (1000ml) of calcium carbonate suspension
| Title | Consumption |
| Calcium carbonate | 50g |
| Arabic gum | 69g |
| Tragacanth | 5g |
| Xylitol | 60 |
| Stevioside | 1g |
| Methyl parahydroxybenzoate | 1.2g |
| Essence | 1.0ml |
Embodiment 5
The preparation (1000ml) of calcium carbonate suspension
| Title | Consumption |
| Calcium carbonate | 50g |
| Arabic gum | 77g |
| Tragacanth | 4g |
| Xylitol | 60 |
| Stevioside | 1g |
| Methyl parahydroxybenzoate | 1.2g |
| Essence | 1.0ml |
Above-described embodiment 4 and embodiment 5, sedimentation volume ratio is 1, is qualified suspension.
Embodiment 6
The preparation (1000ml) of calcium carbonate suspension
| Title | Consumption |
| Calcium carbonate | 50g |
| Glucose | 50g |
| Stevioside | 1g |
| Methyl parahydroxybenzoate | 1.2g |
| Essence | 1.0ml |
In above-described embodiment, contained glucose amount is too many, and be not suitable for diabetic to take, with glucose as suspending agent, suspendible effect is undesirable, easy sedimentation, and sedimentation volume ratio is 0.25, defective.
Embodiment 7
The preparation (1000ml) of calcium carbonate suspension
| Title | Consumption |
| Calcium carbonate | 50g |
| Polyvinylpyrrolidone | 100g |
| Xylitol | 70 |
| Stevioside | 1g |
| Methyl parahydroxybenzoate | 1.4g |
| Essence | 1.0ml |
Above-described embodiment 7 is with polyvinylpyrrolidone as suspending agent, and mobility is fine, but in put procedure, stability is bad, cries easy sedimentation, and sedimentation volume ratio is 0.85.
Embodiment 8
The present invention is to the therapeutical effect of tretinoin Induced Osteoporosis of Rats disease
Osteoporosis reduces with bone amount, and the microstructure degeneration of bone is feature, causes the fragility of bone to increase so that there is a kind of systemic skeletal disease of fracture.
3 month female SD rats 100 are saline control group (NS, 10mlkg according to the balanced random assortment of body weight
-1), model group (tretinoin 80mgkg
-1, gavage, once a day, two weeks), Gaierqi D (vitamin D3 and calcium carbonate) group (gastric infusion 10mlkg
-1, once a day, containing 60mg calcium), high, normal, basic 3 various dose group (10mlkg of the present invention
-1, 30mg, 60mg, 120mg).The while of four treatment groups, gastric infusion tretinoin 2 weeks, then continues administration 6 weeks.After last administration 24 hours, intravenous injection urethane anesthetized rat, took rat femur, and borne densitometers measures bone density (totally 2 points: greater trochanter and cadre).
Note: compare with NS matched group,
△p<0.05,
△ △p<0.01; Compare with model group,
*p<0.05,
*p<0.01.
Above result shows, four treatment groups all can make rat bone density raise.Especially be excellent with the middle and high dosage group of calcium carbonate suspension of the present invention and Gaierqi D (vitamin D3 and calcium carbonate) group, rat bone density can be made to return to normal level.
The foregoing is only preferred embodiment of the present invention, and be not used to limit substantial technological context of the present invention, substantial technological content of the present invention is broadly defined in the right of application, any technology entities that other people complete or method, if with application right define identical, also or a kind of change of equivalence, be all covered by being regarded as among this right.
Claims (8)
1. the suspension containing calcium carbonate, it is characterized in that, in described suspension, the weight ratio of calcium carbonate and suspending agent is 0.2-3.0:1; Preferred 0.3-2.0:1; More preferably 0.5-1.5:1.
2. suspension as claimed in claim 1, is characterized in that, correctives, the antiseptic of 0.05-0.21w/v% and the essence of 0.1-5.0w/v% also containing 4-35w/v% in described suspension.
3. suspension as claimed in claim 1, it is characterized in that, described suspending agent be selected from ethyl cellulose, chitin, tragacanth, arabic gum, hydroxypropyl methylcellulose, polyvinylpyrrolidone, glucose, dextrin and pectin one or more; One or more preferably in tragacanth, arabic gum, polyvinylpyrrolidone and pectin; More preferably from tragacanth and/or arabic gum.
4. suspension as claimed in claim 2, is characterized in that, described correctives be selected from stevioside, aspartame, fructose, xylitol and sucrose one or more; One or more preferably in xylitol, Aspartane and stevioside; More preferably from xylitol and/or stevioside.
5. suspension as claimed in claim 2, is characterized in that, described antiseptic be selected from potassium sorbate, benzylidene sorbitol, sodium benzoate, methyl parahydroxybenzoate and ethylparaben one or more; One or more preferably in benzylidene sorbitol, sodium benzoate, methyl parahydroxybenzoate and ethylparaben; Be more preferably methyl parahydroxybenzoate.
6. the suspension as described in any one of claim 1-5, is characterized in that, described calcium carbonate is precipitated calcium carbonate, and particle diameter is 10-30 μm.
7. a preparation method for the suspension as described in any one of claim 1-6, is characterized in that, described method comprises step:
(1) suspending agent infiltrated by ethanol and water mixing, obtain solution 1;
(2) calcium carbonate and solution 1 are mixed, obtain solution 2;
(3) aqueous solution containing correctives, antiseptic and essence and solution 2 are mixed, obtain the suspension as described in any one of claim 1-6.
8. a purposes for the suspension as described in any one of claim 1-6, is characterized in that, the preparation being used as treatment or prevention calcium deficiency or the medicine of disease caused for the preparation for the treatment of or prevention calcium deficiency and/or calcium deficiency.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310573059.5A CN104622893A (en) | 2013-11-13 | 2013-11-13 | Suspension containing calcium carbonate and preparation method as well as usage thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310573059.5A CN104622893A (en) | 2013-11-13 | 2013-11-13 | Suspension containing calcium carbonate and preparation method as well as usage thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104622893A true CN104622893A (en) | 2015-05-20 |
Family
ID=53202455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310573059.5A Pending CN104622893A (en) | 2013-11-13 | 2013-11-13 | Suspension containing calcium carbonate and preparation method as well as usage thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104622893A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368638B1 (en) * | 1998-03-11 | 2002-04-09 | Smithkline Beecham Corporation | Process of making an aqueous calcium carbonate suspension |
| CN1448143A (en) * | 2002-04-03 | 2003-10-15 | 高华 | Prescription composition of calcium carbonate dry-mixing suspension agent |
| CN1517098A (en) * | 2003-01-16 | 2004-08-04 | 吴建中 | Calcium aluminium suspension |
| CN1587056A (en) * | 2004-07-09 | 2005-03-02 | 胡志彤 | High purity medicinal calcium carboante and its producing method |
| CN101247731A (en) * | 2005-06-16 | 2008-08-20 | 德拉沃有限责任公司 | Calcium fortification of bread dough |
| CN102067997A (en) * | 2009-11-25 | 2011-05-25 | 胡志彤 | High-density calcium carbonate particles |
-
2013
- 2013-11-13 CN CN201310573059.5A patent/CN104622893A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368638B1 (en) * | 1998-03-11 | 2002-04-09 | Smithkline Beecham Corporation | Process of making an aqueous calcium carbonate suspension |
| CN1448143A (en) * | 2002-04-03 | 2003-10-15 | 高华 | Prescription composition of calcium carbonate dry-mixing suspension agent |
| CN1517098A (en) * | 2003-01-16 | 2004-08-04 | 吴建中 | Calcium aluminium suspension |
| CN1587056A (en) * | 2004-07-09 | 2005-03-02 | 胡志彤 | High purity medicinal calcium carboante and its producing method |
| CN101247731A (en) * | 2005-06-16 | 2008-08-20 | 德拉沃有限责任公司 | Calcium fortification of bread dough |
| CN102067997A (en) * | 2009-11-25 | 2011-05-25 | 胡志彤 | High-density calcium carbonate particles |
Non-Patent Citations (1)
| Title |
|---|
| 天津化工研究院等编: "无机盐工业手册", 《无机盐工业手册（第三版上册）》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278928B (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| EP2862575B1 (en) | Application of piceatannol-3'-o-b-d-glucopyranoside in preparation of medicaments for improving microcirculation block | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN104622893A (en) | Suspension containing calcium carbonate and preparation method as well as usage thereof | |
| CN104839846A (en) | Ginseng functional health sports drink and preparation method thereof | |
| CN104223073A (en) | Food, health-care product or pharmaceutical composition for sleep aiding | |
| CN1313112C (en) | Medicinal composition with nourishing and tranquilizing | |
| CN108186631A (en) | A kind of pharmaceutical composition and its preparation method and application | |
| CN104000877A (en) | Blood glucose reducing composition and application thereof | |
| CN108159352A (en) | A kind of drug of soothing liver-qi stagnation | |
| US9399024B2 (en) | Konjac formulation and method for preparing the same | |
| JP5823131B2 (en) | A composition containing windproof tsushosan | |
| CN1857656A (en) | Application of plantain herb in preparing medicine and health article with lead removal promoting effect | |
| CN102008554B (en) | Chinese medicinal mixture for treating upper gastrointestinal bleeding | |
| CN105920035A (en) | Oral particles for acute pancreatitis prognostic nursing | |
| CN103638020A (en) | Novel pharmaceutical composition for treating gout | |
| CN1899421A (en) | Chinese medicine composition for treating angiitis and phlebitis | |
| CN103705602B (en) | Traditional Chinese medicine composition for treating or improving insomnia as well as preparation method and application thereof | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN102125546B (en) | Composition for preventing renal calculi | |
| CN115990166A (en) | A pharmaceutical composition for preventing CT contrast medium nephropathy and its application | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| JP2005350450A (en) | Drug or food for prophylaxis/treatment of circulatory disorder and lifestyle-related disease | |
| CN106822867A (en) | Clinical liver disease nutritional agents and its application | |
| CN104161764B (en) | The application for the treatment of psoriasis is prepared containing the pharmaceutical composition of kushenin and glycyrrhizic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150520 |
|
| RJ01 | Rejection of invention patent application after publication |